Nuvalent, Inc. (NUVL), a company focused on cancer treatment, announced on Monday that it has commenced an underwritten public offering of $350 million of its class A shares. All shares are being offered by Nuvalent.
The drug maker expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of class A shares sold in the public offering.
J.P. Morgan, TD Cowen, Jefferies and Stifel are acting as joint book-running managers for the offering.
For comments and feedback: editorial@rttnews.com